Publicaciones en las que colabora con EDUARDO DÍAZ-RUBIO GARCÍA (42)

2019

  1. Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer

    Future Oncology, Vol. 15, Núm. 3, pp. 271-280

2013

  1. Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer

    Oncologist, Vol. 18, Núm. 8, pp. 917-923

2011

  1. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

    Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136

  2. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review

    Clinical and Translational Oncology, Vol. 13, Núm. 2, pp. 121-132

2009

  1. Circulating tumor cells in metastatic breast cancer: Timing of blood extraction for analysis

    Anticancer Research, Vol. 29, Núm. 10, pp. 4185-4187

2008

  1. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer

    Journal of Chemotherapy, Vol. 20, Núm. 5, pp. 632-639

2006

  1. Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients

    Clinical and Translational Oncology, Vol. 8, Núm. 11, pp. 826-829

  2. Significance of the immunohistochemical detection of lymph node micrometastases in Stage II Colorectal Carcinoma

    Clinical and Translational Oncology, Vol. 8, Núm. 9, pp. 676-680

2005

  1. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer

    Clinical Breast Cancer, Vol. 6, Núm. 4, pp. 325-329

2004

  1. Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure

    Clinical Breast Cancer, Vol. 5, Núm. 5, pp. 353-357

2003

  1. Docetaxel extravasation: A case report

    Clinical and Translational Oncology, Vol. 5, Núm. 1, pp. 47-48

  2. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group

    Annals of Oncology, Vol. 14, Núm. 6, pp. 833-842

  3. Extravasación de taxotere: a propósito de un caso

    Revista de oncología: Publicación oficial de la Federación de Sociedades Españolas de Oncología y del Instituto Nacional de Cancerología de México, Vol. 5, Núm. 1, pp. 47-48

  4. High-dose DICEP chemotherapy versus observation in metastatic breast cancer patients with monotopic disease responding to induction chemotherapy with paclitaxel plus epirubicin. Final results of a phase III GEICAM trial

    Clinical and Translational Oncology, Vol. 5, Núm. 3, pp. 148-155

2002

  1. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: Results of a randomized study

    Revista Espanola de Quimioterapia, Vol. 15, Núm. 3, pp. 257-263

2001

  1. Prognostic value of DNA quantification in early epithelial ovarian carcinoma

    Obstetrics and Gynecology, Vol. 97, Núm. 3, pp. 409-416

2000

  1. Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: A Phase II study

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 23, Núm. 6, pp. 617-621

  2. Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure

    Annals of Oncology, Vol. 11, Núm. 1, pp. 85-89

1998

  1. End-stage acute hepatic failure as clinical presentation of liver metastases from breast cancer

    Tumori, Vol. 84, Núm. 5, pp. 616-617

  2. Preliminary Results of a Phase II Study: Paclitaxel Plus Vinorelbine in Metastatic Breast Ca Patients with Contraindications to Receive Anthracyclines

    ONCOLOGY, Vol. 12, Núm. 1 SUPPL.1, pp. 28-30